Central Garden Pet (GP7) Q2 2026 Earnings Report

The call presented a largely positive operating and financial picture: record Q2 and first-half results, top-line growth (+9% consolidated), margin expansion, improved adjusted EBITDA, strong segment performance (Pet +5%, Garden +13% in Q2), and a robust balance sheet. Strategic simplification and the Phillips JV position the company to focus on higher-margin branded growth, though the JV will reduce reported revenue in the near term and bring a modest initial EPS headwind. Key risks include weather-dependent sell-through (May is pivotal), input cost inflation (notably urea) that may require future pricing, and a promotional retail environment with some private-label pressure. Overall, the positive operational execution, liquidity, and margin improvement outweigh the near-term headwinds and timing risks.

Central reiterated its Fiscal 2026 non‑GAAP diluted EPS guidance of $2.70 or better, supported by a strong Q2 that included net sales of $906M (+9% YoY), gross profit of $300M and a 33.1% gross margin (+30 bps), operating income of $114M (12.6% margin), net income of $79M, diluted EPS of $1.28, and adjusted EBITDA of $139M (15.4% margin), and by a first‑half showing of sales +2%, gross margin +70 bps and operating income +8%; they noted the recently announced JV will lower reported H2 revenue by a low‑teens percentage (with an initial conservative EPS headwind of $0.03–$0.05 in H2 and minimal long‑term earnings impact), CapEx is expected to be ~$50–$60M for the year (Q2 CapEx $10M, D&A $21M), cash & short‑term investments totaled $653M, total debt $1.2B, gross leverage was 2.8x (below their 3.0–3.5x target) and net leverage ~1.3x, and the guidance excludes impacts from future acquisitions, divestitures or restructurings.